BioSpace News Archive

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported interim results from the ongoing ACROBAT Edge Phase 2 trial.

Luminex Corporation announced 1st quarter 2020 revenues of just over $90 million, up approximately 10% over the 1st quarter of 2019 and approximately 8% above the top end of its previously communicated 1st quarter revenue guidance range of $82 to $84 million.

Timber Pharmaceuticals LLC announced the company has been awarded the second tranche of $500,000 of the $1.5 million grant from the U.S. Food & Drug Administration Office of Orphan Products Development Orphan Products Clinical Trials Grants Program after reaching certain clinical milestones in the development of TMB-001.

Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders

Encompass Health Corp. announced it will award frontline employees in its 134 hospitals, 245 home health locations and 83 hospice locations with additional paid time off in recognition of their outstanding efforts during the COVID-19 outbreak.

BD announced that it will conduct a live webcast of its second fiscal quarter 2020 earnings conference call on Thursday, May 7, 2020, at 8:00 a.m.

IQVIA™, a leader in Human Data Science, announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.

Imports to supplement the 35 million N95 respirators 3M currently produces in U.S. per month

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that its Board of Directors (Board) has appointed Harout Semerjian as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 16, 2020.

Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Severely Calcified Coronary Arteries